Analyzing Immuneering (NASDAQ:IMRX) and Axsome Therapeutics (NASDAQ:AXSM)

Immuneering (NASDAQ:IMRX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Institutional & Insider Ownership

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 22.3% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Immuneering and Axsome Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$61.04 million	($1.78)	-2.66
Axsome Therapeutics	$385.69 million	24.25	-$287.22 million	($4.67)	-39.73

Immuneering has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Immuneering and Axsome Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1	0	5	1	2.86
Axsome Therapeutics	2	0	19	0	2.81

Immuneering currently has a consensus price target of $16.50, indicating a potential upside of 248.10%. Axsome Therapeutics has a consensus price target of $208.72, indicating a potential upside of 12.49%. Given Immuneering’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Immuneering is more favorable than Axsome Therapeutics.

Risk and Volatility

Immuneering has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares Immuneering and Axsome Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-73.49%	-65.01%
Axsome Therapeutics	-40.90%	-277.31%	-28.81%

Summary

Immuneering beats Axsome Therapeutics on 10 of the 14 factors compared between the two stocks.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.